If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Novelia is now commercialized for the first time for glaucoma in Latin America!

    Quick Contact
    Novelia is now commercialized for the first time for glaucoma in Latin America!

    Our preservative-free multidose eyedropper has been launched in Paraguay with different formulations (branded OFTALMICA):

    • Latanoprost
    • Latanoprost + Timolol
    • Dorzolamide + Timolol

    The use of preservatives can cause allergies or ocular irritation, and some can even cause a toxic response, damaging patients’ eyes[*]. These reactions are even more pronounced when the patient uses combination therapies.

    For this reason, patients under chronic treatment, like glaucoma, will appreciate the unpreserved formulations delivered with the multidose Novelia® system.

    User-friendly and intuitive, Novelia contributes to improve patients’ life, allowing the delivery of safe unpreserved eye drops and improving the patients’ adherence to treatments.

    Novelia has also been commercialized in Paraguay for artificial tears, decongestants and anti-allergy applications.

    [*] Report of the International Dry Eye Workshop. Ocul Surf 2007; 5[2]; 65-204.

    Files

    See also

    Nemera's RetroNose enhances therapeutic efficacy of nasal treatments

    The number of applications through the nasal route is expanding, either for local treatments (e.g. chronic rhinosinusitis) or for systemic treatments (e.g. migraine, etc.). The clinical efficacy of a nasal treatment depends on how it is deposited in the nose, because the pharmaceutical target (local, systemic, brain) is directly related to a specific nasal anatomical site. That’s why Nemera has collaborated with CEPR to develop a different and portable delivery technology called RetroNose for a better drug deposition in the distal region of the nose, without lung deposition.

    e-Novelia wins the ‘Excellence in Pharma: Drug Delivery Devices’ award at CPhI Worldwide 2018

    On October 9th, during the CPhI Pharma Awards Gala, e-Novelia®, Nemera’s electronic add-on for ophthalmic droppers, was celebrated as the best-in-class innovation displayed at the show for “Excellence in Pharma: Drug Delivery Devices”. e-Novelia®, Nemera’s smart ophthalmic add-on, has been designed to make patients’ life easier, by offering increased comfort and optimized adherence to their treatments.

    Safelia 1ml and 2.25ml autoinjectors designed to be patient and syringe friendly

    Nemera’s new generation 2-step autoinjector platforms are suitable for fluid to highly viscous injections. Safelia® has been designed to ease patient self-injection experience and to deliver even the most challenging drugs (viscous formulations up to several Centipoise, sustain released, concentrated, fragile and shear sensitive formulations, either in subcutaneous or intramuscular layers, on two platforms: up to 1ml or up to 2.25ml delivery).

    • Marine Silarbi
    • Product Info
    • English
    • Created 30 Aug 2016
    • Modified 12 Sep 2016
    • Hits 3441
    Webpackaging
    CTLpack
    Cosfinity